Medivir Q3 2023: The Case for Fostrox Strengthens - Redeye

Redeye comments on Medivir's Q3 report and on the new positive data from 18 patients in the liver cancer trial treated with fostrox + Lenvima. We raise our base case and remodel our bull and bear cases to better reflect potential outcomes with fostrox.

Länk till analysen i sin helhet: https://www.redeye.se/research/952177/medivir-q3-2023-the-case-for-fostrox-strengthens?utm_source=finwire&utm_medium=RSS